Categories: Market Research

Retinal Disorder Treatment Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Retinal Disorder Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Retinal Disorder Treatment Market:

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

According to The Business Research Company’s Retinal Disorder Treatment Global Market Report 2024, The retinal disorder treatment market size has grown rapidly in recent years. It will grow from $11.57 billion in 2023 to $12.74 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to introduction of anti-vegf therapies, aging population, increased incidence of retinal disorders, improved diagnostic tools for early detection, increased awareness and screening programs, expanded access to healthcare services.

The retinal disorder treatment market size is expected to see strong growth in the next few years. It will grow to $17.93 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to patient-centric approaches in retinal healthcare, increasing global healthcare expenditure, greater focus on combination therapies for retinal disorders, rise of home-based retinal disorder monitoring, increasing adoption of implantable devices for retina treatment, adoption of regenerative medicine in retina treatment

Major trends in the forecast period include advancements in ophthalmic imaging technologies, development of minimally invasive surgical techniques, integration of artificial intelligence in diagnostics, advancements in drug delivery technologies, integration of virtual reality in retinal rehabilitation, collaboration between research institutions and pharmaceutical companies, development of gene therapies for genetic retinal diseases.

The growing incidence of retinal disorders is expected to propel the growth of the retinal disorder treatment market going forward. Retinal diseases refer to medical conditions that affect the retina and the light-sensitive tissue at the back of the eye and can cause vision loss or severe visual impairment. Retinal disorder treatments help control and reduce the symptoms of retinal disorders by providing treatments such as laser therapy, vitrectomy, and retinal implants. For instance, in January 2023, according to the International Agency for the Prevention of Blindness, a UK-based international alliance, age-related macular degeneration (AMD) is projected to be responsible for about 5% of all blindness worldwide. Additionally, age-related macular degeneration diseases are expected to impact 288 million people by 2040. Therefore, the growing incidence of retinal disorders is driving the growth of the retinal disorder treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12701&type=smp

The retinal disorder treatment market covered in this report is segmented –

1) By Type: Macular Degeneration, Diabetic Retinopathy, Other Types

2) By Dosage Form: Gels, Eye Solutions, Capsules And Tablets, Eye Drops, Ointments

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Product innovations are a key trend gaining popularity in the retinal disorder treatment market. Major companies operating in the retinal disorder treatment market are introducing new products to sustain their position in the market. For instance, in January 2022, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Vabysmo, a bispecific antibody used to treat neovascular or wet age-related macular degeneration (AMD) and diabetic macular edema (DME). It is the first injectable eye medication that targets and inhibits two disease pathways that include angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), linked to retinal diseases that may reduce vision. Clinical trials showed non-inferior vision improvements compared to conventional therapy, with a good safety profile. The approval represents a significant step forward in treating retinal diseases and offers patients the possibility of better eyesight and a lighter treatment load.

The retinal disorder treatment market report table of contents includes: